| Literature DB >> 31280699 |
Khary Adams1, Donna Clemons2, Lynn Collura Impelluso3, Donna Lee4, Sean Maguire5, Alexis Myers6, Christopher Petursson7, Robert Schulingkamp8, Kevin Trouba8, Matthew Wright9.
Abstract
The recent Scientific Committee on Health, Environmental and Emerging Risks Final Opinion on "The need for nonhuman primates in biomedical research, production and testing of products and devices" (2017 SCHEER) highlights approaches that could significantly contribute to the replacement, reduction, and refinement of nonhuman primate (NHP) studies. Initiatives that have the potential to affect NHP welfare and/or their use are expected to be appropriate, fair, and objective and publicly disseminated information focused on NHPs in biomedical research, which includes toxicologic and pathologic research and testing, should be objectively evaluated by stakeholder scientists, researchers, and veterinarians. Thus, IQ Consortium member companies convened to develop an informed and objective response, focusing on identifying areas of agreement, potential gaps, or missing information in 2017 SCHEER. Overall, the authors agree that many positions in the 2017 SCHEER Opinion generally align with industry views on the use of NHPs in research and testing, including the ongoing need of NHPs in many areas of research. From the perspective of the IQ Consortium, there are several topics in the 2017 SCHEER that merit additional comment, attention, or research, as well as consideration in future opinions.Keywords: (xeno)transplantation; DruSafe (IQ Consortium Preclinical Safety Leadership Group); IQ; SCHEER; biomedical research; infectious diseases; neuroscience; nonhuman primate; ophthalmology; safety; scientific Opinion; testing; toxicology; vaccines
Mesh:
Year: 2019 PMID: 31280699 DOI: 10.1177/0192623319857976
Source DB: PubMed Journal: Toxicol Pathol ISSN: 0192-6233 Impact factor: 1.902